Dr. Carlyle began her training as an Undergraduate at the University of Oxford, where she gained a First Class degree in Medical Sciences in 2005. Rather than continue to complete her medical training, she felt the pull of molecules and sample tubes, and transitioned to complete a Ph.D. at the University of Edinburgh, where she studied the downstream signaling interactions of a schizophrenia risk gene, DISC1. Upon completion of her Ph.D. in 2010, she moved to the USA, where she was trained in proteomic and transcriptomic analysis of brain tissue in the labs of Dr. Arthur Simen and Professor Angus Nairn. In 2017 she was recruited to the Alzheimer’s Clinical and Translational Research Unit (ACTRU) at Massachusetts General Hospital / Harvard Medical School by Professor Steven Arnold. She is currently an Instructor in Neurology, leading biomarker discovery projects and proteomics informed mechanistic studies with the ultimate goal of developing more informative biomarkers for Alzheimer’s Disease that can be used in novel Clinical Trials.
Becky Carlyle, PhD
First published on: July 02, 2019
Last modified on: November 23, 2024